Clinical Trial Update: A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of particle size on bioequivalence and bioavailability, sponsored by GlaxoSmithKline, and the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Chronic Obstructive Pulmonary Disease
• Rheumatoid Arthritis

Drugs mentioned

• Not disclosed

Snippet

Sponsor: GlaxoSmithKline | Conditions: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis | Phase 1 | Status: COMPLETED